DR's orders: Human antibody kills tumors by direct signaling

Nature Medicine

Volumn 8, Issue 8, 2002, Pages 781-783

  Longo, Dan L ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; GEMTUZUMAB OZOGAMICIN; HLA DR ANTIGEN; HUMAN MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL DEATH; CLINICAL TRIAL; DRUG APPROVAL; ENZYME ACTIVATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; ISOTOPE LABELING; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; GENETIC ENGINEERING; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY; LYMPHOMA; MICE; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

ANIMALIA; MURINAE;

EID: 0036346930     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0802-781     Document Type: Short Survey

References (12)

1. Fully human, HLA-DR-specific monoclonal antibodies efficient induce programmed death of malignant lymphoid cells
2. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
3. Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-mu of WEHI-231 and the selection and properties of resistant mutants
4. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein
5. T-cell tumor elimination as a result of T-cell-receptor-mediated activation
6. Inhibition of human B-cell lymphoma growth by CD 40 stimulation
7. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts
8. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs
9. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B-cell lymphoma
10. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
11. Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma
12. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma